Oncorena Presents Two Abstracts on Orellanine at the Nordic Society of Nephrology
LUND, SWEDEN, May 23, 2022 – Oncorena presented two abstracts on orellanine at the Nordic Society of Nephrology, in Odense, Denmark on May 4-7. Oncorena is developing orellanine as a potential breakthrough therapy for advanced kidney cancer.
At the 36th biennial congress of the Nordic Society of Nephrology the following two abstracts on orellanine were presented by the Oncorena team.
- Abstract #P70 presents the rationale and the protocol of the newly initiated clinical trial Oncorella-1, or ONC001-CL-001. For more details please consult ClinicalTrials.gov NCT05287945.
- Abstract #P78 contains preclinical data on the hyper-acute kidney injury triggered by orellanine – a compound that does not seem to have any off-target effects.
Oncorena’s drug candidate orellanine, which has an unique mode of action, is being developed for organ-specific chemotherapy with curative potential for patients with advanced kidney cancer undergoing dialysis due to kidney failure. The company’s Phase I-II clinical trial of orellanine, the first-in-class compound, was initiated in February 2022. The study is conducted at the Centre for Clinical Cancer Studies at the Karolinska University Hospital in Stockholm, Sweden, and will study safety, tolerability, pharmacokinetics and signs of anti-tumour effects in treatment with a synthetic form of orellanine.
For further information, please contact
Lars Grundemar, M.D., Ph.D., Chief Executive Officer, Oncorena AB
Telephone +46 (0)76 209 5518
Orellanine, which has a new and unique mode of action, is being developed for organ-specific chemotherapy with curative potential for patients with advanced renal cancer undergoing dialysis. Orellanine is found in mushrooms of the Cortinarius family, these are sometimes accidentally picked and eaten as they are mistaken for funnel chanterelles. The clinical effects of orellanine are well documented and are completely limited to the kidneys. Orellanine is expected to have positive effect on the two most common forms of kidney cancer: Clear-Cell and Papillary Kidney Cancer. About 90% of kidney cancer patients are affected by these types of cancer.
About kidney cancer
Approximately 400,000 patients are affected by kidney cancer globally according to the WHO. The disease can often be cured by surgery if detected in time, but unfortunately the diagnosis is often made when the tumour has already spread to other organs. The prognosis is then considerably less favourable and certain groups have a median survival of less than two years. Today the disease is treated with various types of targeted and immuno-active drugs, often with severe side effects, and standard chemotherapy drugs have limited effect. There is therefore a great and urgent unmet medical need for new, effective and safe drugs.
Oncorena AB is a Swedish pharma company headquartered in Lund. The company develops a new potential breakthrough treatment for patients with advanced kidney cancer. The treatment is based on research at the University of Gothenburg, Sweden, led by professors Börje Haraldsson and Jenny Nyström. The project was initially developed with support from Vinnova, Sweden’s Innovation Agency, GU Ventures at the University of Gothenburg and private business angels. Today Oncorena is mainly financed by the investment companies HealthCap, Linc AB, Fåhraeus Startup and Growth AB, as well as the biotech company AQILION AB.
For more information, please visit Oncorena´s website at www.oncorena.com